Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FOXK2 in Skeletal Muscle Development: A New Pathogenic Gene for Congenital Myopathy with Ptosis

ABSTRACT: FOXK2 in Skeletal Muscle Development: A New Pathogenic Gene for Congenital Myopathy with Ptosis

PROVIDER: PRJNA1234572 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

FOXK2 in Skeletal Muscle Development: A New Pathogenic Gene for Congenital Myopathy with Ptosis

Project description:Congenital ptosis, a genetic disorder involving levator palpebrae muscle dysfunction, is often associated with congenital myopathy. The genetic causes of this condition remain poorly understood. In this study, we identified FOXK2 mutations in six pedigrees with congenital myopathy and ptosis through whole exome sequencing and Sanger sequencing. Zebrafish with foxk2 deficiency exhibited underdeveloped skeletal muscles and reduced mobility, while mice with Foxk2 deletion in skeletal muscle stem cells (MuSCs) showed generalized skeletal muscle abnormalities. Further analysis revealed that FOXK2 deficiency impaired myogenic differentiation in C2C12 cells and disrupted mitochondrial homeostasis in both mouse MuSCs and C2C12 cells. Rescue experiments confirmed the loss-of-function effects of FOXK2 mutation. Coenzyme Q10 treatment improved mitochondrial function and alleviated skeletal muscle development defects in Foxk2-deficient mice. Preliminary omics analysis suggested FOXK2 directly regulates the expression of mitochondrial function-related genes by modulating chromatin accessibility at its binding sites. Our study identifies FOXK2 as a novel pathogenic gene for congenital myopathy with ptosis and highlights its essential role in skeletal muscle development and mitochondrial homeostasis, offering insights for potential diagnostics and therapies.

2025-07-01 | GSE291642 | GEO

FOXK2 in skeletal muscle development: a new pathogenic gene for congenital myopathy with ptosis.

Project description: Not available

| S-EPMC12254393 | biostudies-literature

FOXK2 in Skeletal Muscle Development: A New Pathogenic Gene for Congenital Myopathy with Ptosis

Project description: Not available

| S-BSST1949 | biostudies-other

FOXK2 in Skeletal Muscle Development: A New Pathogenic Gene for Congenital Myopathy with Ptosis

Project description: Not available

| S-SCDT-10_1038-S44321-025-00247-X | biostudies-other

Dysregulation of muscle myosin biochemical states in X-linked myotubular myopathy

Project description:Pathogenic variants in MTM1 are associated with a severe, congenital muscle disorder called X-linked myotubular myopathy. Here, we aimed to assess the effect of mavacamten (myosin ATPase inhibitor) treatment in a mouse model for X-linked myotubular myopathy (Mtm1-KO) using the global untargeted proteomics approach. We used skeletal muscle tissue from Mtm1-KO mice and from WT mice, both treated and not treated with mavacamten.

2025-10-31 | PXD068387 | Pride

Mitochondrial dysfunction in Nemaline myopathy type 6

Project description:Nemaline Myopathy type 6 (NEM6) is a congenital myopathy caused by variants in KBTBD13...

2026-06-29 | PXD071917 | Pride

Comparative Genomic Hybridization: genomic control vs. Ullrich Congenital Muscular Dystrophy and Bethlem myopathy

Project description:Molecular characterization of collagen-VI related myopathies currently relies on standard sequencing, which yields a detection rate approximating 75-79% in Ullrich congenital muscular dystrophy (UCMD) and 60-65% in Bethlem myopathy (BM) patients as PCR-based techniques tend to miss gross genomic rearrangements as well as copy number variations (CNVs) in both the coding sequence and intronic regions. We have designed a custom oligonucleotide CGH array in order to investigate the presence of CNVs in the coding and non-coding regions of COL6A1, A2, A3, A5 and A6 genes and a group of genes functionally related to collagen VI. A cohort of 12 patients with UCMD/BM negative at sequencing analysis and 2 subjects carrying a single COL6 mutation whose clinical phenotype was not explicable by inheritance were selected and the occurrence of allelic and genetic heterogeneity explored. A deletion within intron 1A of the COL6A2 gene, occurring in compound heterozygosity with a small deletion in exon 28, previously detected by routine sequencing, was identified in a BM patient. RNA studies showed monoallelic transcription of the COL6A2 gene, thus elucidating the functional effect of the intronic deletion. No pathogenic mutations were identified in the remaining analyzed patients, either within COL6A genes, or in genes functionally related to collagen VI. Our custom CGH array may represent a useful complementary diagnostic tool, especially in recessive forms of the disease, when only one mutant allele is detected by standard sequencing. The intronic deletion we identified represents the first example of a pure intronic mutation in COL6A genes. Comparative Genomic Hybridization experiment. Experimental Replicates: twice

2010-01-27 | E-GEOD-20025 | biostudies-arrayexpress

FOXK2 promotes AP-1 mediated transcriptional regulation - transcription profiling FOXK2 induction

Project description:Transcription profiling of FOXK2 expression in HeLa cells from a stably integrated doxycyline-inducible EGFP-FOXK2 expression construct.

2011-11-03 | E-MEXP-3040 | biostudies-arrayexpress

FOXK2 ChIP-seq

Project description:Chromatin immunoprecipitation of FOXK2 (tagged with Flag and His tags) in U2OS cells detected by SOLiD sequencing. ***Correction March 2014: The sample “FOXK2_Dox_treated” has been renamed, it was originally named “FOXK2_rep2”. A new sample “FOXK2_rep2” has been added, with new files. It has come to our attention that one of the FOXK2 ChIP-seq replicates 'FOXK2_rep2' that we used in our paper recent paper (Ji, Z., Donaldson, I.J., Liu, J., Hayes, A., Zeef, L.A.H. and Sharrocks, A.D. (2012) The forkhead transcription factor FOXK2 promotes AP-1-mediated transcriptional regulation. Mol. Cell. Biol. 32, 385-398. doi:10.1128/MCB.05504-11) was incorrect. The replicate was actually treated with doxorubicin prior to ChIP-seq analysis resulting in the loss of many FOXK2 binding events.***

2011-01-20 | E-MTAB-565 | biostudies-arrayexpress

FOXK2 ChIP-seq

Project description:FOXK2 ChIP-seq

| PRJEB2447 | ENA